

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent	Form	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden hours
Physician	CDC 4.422-1	200	1	10/60	33
Total					33

Jeffrey M. Zirger,

*Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.*

[FR Doc. 2020-01051 Filed 1-21-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[OMB No. 0970-0492]

Submission for OMB Review; Community Services Block Grant Annual Report

AGENCY: Office of Community Services;
Administration for Children and
Families; HHS.

ACTION: Request for public comment.

SUMMARY: The Administration of
Children and Families (ACF), Office of
Community Services (OCS) is requesting
a three-year extension with minor

changes of the Community Services
Block Grant (CSBG) Annual Report
(OMB No.: 0970-0492, expiration 1/31/
2020). This request will support the
currently utilized CSBG Annual Report,
comprised of Modules 1-4, and
incorporates performance management.

DATES: *Comments due within 30 days of
publication.* OMB is required to make a
decision concerning the collection of
information between 30 and 60 days
after publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.

ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
directly to the following: Office of
Management and Budget, Paperwork
Reduction Project, Email: *OIRA_*
SUBMISSION@OMB.EOP.GOV, Attn:
Desk Officer for the Administration for
Children and Families.

Copies of the proposed collection may
be obtained by emailing *infocollection@*

acf.hhs.gov. Alternatively, copies can
also be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research,
and Evaluation (OPRE), 330 C Street
SW, Washington, DC 20201, Attn: OPRE
Reports Clearance Officer. All requests,
emailed or written, should be identified
by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: Module 1 includes minor
edits to align with the updated, and
OMB approved, CSBG State Plan.
Module 2, Module 3, and Module 4
include only technical and grammatical
updates for ease and clarity of current
reporting. Copies of the proposed
collection of information can be
obtained by visiting: *http://*
www.acf.hhs.gov/programs/ocs/
programs/csbgs.

Respondents: State governments,
including the District of Columbia and
the Commonwealth of Puerto Rico, and
U.S. territories and CSBG eligible
entities (Community Action Agencies).

Annual Burden Estimates:

Instrument	Annual number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
CSBG Annual Report (States)	52	1	198	10,296
CSBG Annual Report (Eligible Entities)	1,009	1	697	703,273

*Estimated Total Annual Burden
Hours:* 713,569.

Authority: 112 Stat. 2729; 42 U.S.C.
9902(2).

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2020-00928 Filed 1-21-20; 8:45 am]

BILLING CODE 4184-27-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2018-E-3053 and FDA-
2018-E-4226]

Determination of Regulatory Review Period for Purposes of Patent Extension; MAVYRET

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for MAVYRET and is publishing this
notice of that determination as required
by law. FDA has made the

determination because of the
submission of applications to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of
patents which claims that human drug
product.

DATES: Anyone with knowledge that any
of the dates as published (see
SUPPLEMENTARY INFORMATION) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by March 23, 2020.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
July 20, 2020. See "Petitions" in the